公开(公告)号：US10550435B2

公开(公告)日：2020-02-04

申请号：US14937942

申请日：2015-11-11

Applicant: NeoGenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12Q1/6886 ,  A61N5/10

Abstract: Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms.

公开(公告)号：US20240241128A1

公开(公告)日：2024-07-18

申请号：US18286040

申请日：2022-04-08

Applicant: NeoGenomics Laboratories, Inc. ,  The University of Sheffield

Inventor： Claire Lewis ,  Anna Juncker-Jensen ,  Mate Levente ,  Nicholas Matthew Stavrou ,  Mohammed Ridha Moamin ,  Richard Allen

IPC: G01N33/574 ,  G01N33/569

CPC classification number: G01N33/57484 ,  G01N33/56972 ,  G01N33/57415 ,  G01N33/57434

Abstract: Provided herein are methods for determining the chance of a tumor not responding to an anti-cancer therapy (e.g., a T cell-based immunotherapy) based on the presence, density, number, and/or location of certain three-cell structures as described herein. The three-cell structures may comprise a T cell, an immunosuppressive tumor-associated macrophage, and an immunosuppressive regulatory T cell. Such methods may be useful for identifying patients not likely to respond to T cell-based immunotherapy. Also provided herein are methods for determining the prognosis and/or invasiveness of a tumor. The present disclosure also encompasses methods for treating a tumor, as well as kits for performing the methods disclosed herein.

公开(公告)号：US10604801B2

公开(公告)日：2020-03-31

申请号：US14937937

申请日：2015-11-11

Applicant: NeoGenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12Q1/6874 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.

公开(公告)号：US10329605B2

公开(公告)日：2019-06-25

申请号：US15134302

申请日：2016-04-20

Applicant: NEOGENOMICS LABORATORIES, INC.

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/6858 ,  C12Q1/6869 ,  C12Q1/6886

Abstract: A method for detecting a low-occurrence mutation in isolated DNA adds a blocking probe to reagents during amplification of the isolated DNA. The blocking probe is an oligonucleotide complementary to wild-type DNA corresponding to the sample. The blocking probe spans a site of a suspected mutation within a region of interest in the isolated DNA. After amplification, fragments of the amplified DNA is sequenced using next generating sequencing and an output is generated to display the sequenced fragments. In some embodiments, the blocking probe is locked nucleic acid (LNA).

公开(公告)号：US20170051357A1

公开(公告)日：2017-02-23

申请号：US15239542

申请日：2016-08-17

Applicant: Neogenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.

Abstract translation: 用于预测慢性淋巴细胞性白血病（CLL）患者中BTK抑制剂抗性的方法通过使用与检测对伊布他滨抗性相关的基因的野生型阻断来增强Sanger测序和NGS的敏感性。 通过使用无细胞DNA可以进一步提高灵敏度。

公开(公告)号：US20170002427A1

公开(公告)日：2017-01-05

申请号：US15201302

申请日：2016-07-01

Applicant: Neogenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/156

Abstract: A method for increasing sensitivity for detecting minority mutations in MYD88 uses a locked nucleic acid oligo to block amplification of wild-type DNA in DNA isolated from patient FFPE tissue, bone marrow aspirate or peripheral blood samples during PCR while still allowing sequencing and visualization of the PCR product. Further improvement to the sensitivity may be achieved by using a uracil DNA-glycosylase treatment to remove sequence artifacts commonly found in formalin-fixed, paraffin-embedded tissue.

Abstract translation: 用于检测MYD88中少数突变的灵敏度的方法使用锁定的核酸寡核苷酸来阻断在PCR期间分离自患者FFPE组织，骨髓抽吸物或外周血样品的DNA中的野生型DNA的扩增，同时仍允许测序和观察 PCR产物。 通过使用尿嘧啶DNA - 糖基化酶处理来消除通常在福尔马林固定的，石蜡包埋的组织中发现的序列假象，可以进一步改善敏感性。

公开(公告)号：US20160169786A1

公开(公告)日：2016-06-16

申请号：US14965640

申请日：2015-12-10

Applicant: NEOGENOMICS LABORATORIES, INC.

Inventor： Maher ALBITAR ,  Hong ZHANG

IPC: G01N15/14 ,  G06K9/00 ,  G06T7/00 ,  C40B30/02

CPC classification number: G01N15/1429 ,  G01N15/1459 ,  G01N2015/1006 ,  G06K9/00127 ,  G06K9/6269 ,  G06K9/6282 ,  G06K9/6287 ,  G16B35/00 ,  G16C20/60

Abstract: An automated method and system are provided for receiving an input of flow cytometry data and analyzing the data using a hierarchical arrangement of analytical elements, each of which utilizes a support vector machine to automatically classify the data into different subpopulations to recognize a pattern within the data. The pattern may be used to generate a diagnostic prediction for a patient or to identify patterns within samples collected from multiple subjects.

Abstract translation: 提供了一种自动化方法和系统，用于接收流式细胞术数据的输入并使用分析元件的分层排列分析数据，每个分析元件利用支持向量机自动将数据分类到不同的子群中以识别数据内的模式 。 该模式可以用于产生患者的诊断预测或者识别从多个受试者收集的样本内的模式。

公开(公告)号：US10253370B2

公开(公告)日：2019-04-09

申请号：US15239542

申请日：2016-08-17

Applicant: Neogenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12Q1/6886

Abstract: A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.

公开(公告)号：US10227657B2

公开(公告)日：2019-03-12

申请号：US15201302

申请日：2016-07-01

Applicant: Neogenomics Laboratories, Inc.

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12Q1/6886

Abstract: A method for increasing sensitivity for detecting minority mutations in MYD88 uses a locked nucleic acid oligo to block amplification of wild-type DNA in DNA isolated from patient FFPE tissue, bone marrow aspirate or peripheral blood samples during PCR while still allowing sequencing and visualization of the PCR product. Further improvement to the sensitivity may be achieved by using a uracil DNA-glycosylase treatment to remove sequence artifacts commonly found in formalin-fixed, paraffin-embedded tissue.

公开(公告)号：US20160340725A1

公开(公告)日：2016-11-24

申请号：US15134302

申请日：2016-04-20

Applicant: NEOGENOMICS LABORATORIES, INC.

Inventor： Maher Albitar

IPC: C12Q1/68

CPC classification number: C12Q1/6858 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2535/122 ,  C12Q2537/159 ,  C12Q2537/163

Abstract: A method for detecting a low-occurrence mutation in isolated DNA adds a blocking probe to reagents during amplification of the isolated DNA. The blocking probe is an oligonucleotide complementary to wild-type DNA corresponding to the sample. The blocking probe spans a site of a suspected mutation within a region of interest in the isolated DNA. After amplification, fragments of the amplified DNA is sequenced using next generating sequencing and an output is generated to display the sequenced fragments. In some embodiments, the blocking probe is locked nucleic acid (LNA).

Abstract translation: 用于检测分离的DNA中的低发生突变的方法在扩增分离的DNA期间向试剂添加封闭探针。 阻断探针是与对应于样品的野生型DNA互补的寡核苷酸。 阻断探针跨越分离的DNA中感兴趣区域内的疑似突变的位点。 扩增后，使用下一个生成测序对扩增的DNA的片段进行测序，并产生输出以显示测序的片段。 在一些实施方案中，阻断探针是锁定核酸（LNA）。